The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will look at the effect of exenatide, a drug which has been approved for the
treatment of type 2 diabetes, on body weight, appetite and energy expenditure among
moderately obese women without diabetes.
The study is 35 weeks long and includes 19 outpatient visits. Participants will receive
exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither
participants nor investigators will know whether exenatide or placebo is being administered.
Participants will be started randomly on either exenatide or placebo.
Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss
and may lead to changes in energy expenditure.
Phase:
Phase 4
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Amylin Pharmaceuticals, LLC. Eli Lilly and Company